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Abstract
Background: The increasing prevalence of type 2 diabetes poses a major public health challenge.
Population-based screening and early treatment for type 2 diabetes could reduce this growing
burden. However, the benefits of such a strategy remain uncertain.
Methods and design: The ADDITION-Cambridge study aims to evaluate the effectiveness and cost-
effectiveness of (i) a stepwise screening strategy for type 2 diabetes; and (ii) intensive multifactorial
treatment for people with screen-detected diabetes in primary care. 63 practices in the East Anglia
region participated. Three undertook the pilot study, 33 were allocated to three groups: no
screening (control), screening followed by intensive treatment (IT) and screening plus routine care
(RC) in an unbalanced (1:3:3) randomisation. The remaining 27 practices were randomly allocated
to IT and RC. A risk score incorporating routine practice data was used to identify people aged
40–69 years at high-risk of undiagnosed diabetes. In the screening practices, high-risk individuals
were invited to take part in a stepwise screening programme. In the IT group, diabetes treatment
is optimised through guidelines, target-led multifactorial treatment, audit, feedback, and academic
detailing for practice teams, alongside provision of educational materials for newly diagnosed
participants. Primary endpoints are modelled cardiovascular risk at one year, and cardiovascular
mortality and morbidity at five years after diagnosis of diabetes. Secondary endpoints include all-
cause mortality, development of renal and visual impairment, peripheral neuropathy, health service
costs, self-reported quality of life, functional status and health utility. Impact of the screening
programme at the population level is also assessed through measures of mortality, cardiovascular
morbidity, health status and health service use among high-risk individuals.
Discussion: ADDITION-Cambridge is conducted in a defined high-risk group accessible through
primary care. It addresses the feasibility of population-based screening for diabetes, as well as the
benefits and costs of screening and intensive multifactorial treatment early in the disease trajectory.
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The intensive treatment algorithm is based on evidence from studies including individuals with
clinically diagnosed diabetes and the education materials are informed by psychological theory.
ADDITION-Cambridge  will provide timely evidence concerning the benefits of early intensive
treatment and will inform policy decisions concerning screening for type 2 diabetes.
Trial registration: Current Controlled trials ISRCTN86769081
Background
Diabetes is an increasingly common problem [1], associ-
ated with a substantial burden of premature mortality,
morbidity, suffering and financial cost through its mac-
rovascular and microvascular complications [2]. The high
proportion (30–50%) of undiagnosed cases of diabetes
[3], the large number of individuals with complications at
clinical diagnosis [4], and the long (9–12 years) latent
phase of the condition [5]. Indeed, type 2 diabetes fulfils
many of the criteria for suitability for screening [6].
Adopting a national policy of population-based screening
for type 2 diabetes could help to reduce the current bur-
den of morbidity and mortality associated with the dis-
ease. However, there is continuing uncertainty about the
benefits and costs of screening for type 2 diabetes. In par-
ticular, modelling data suggest that a key but uncertain
determinant of the cost-effectiveness of screening is the
size of cardiovascular risk reduction consequent on early
intensive multifactorial treatment in screen-detected
patients [7]. There is evidence that intensive multifactorial
treatment is cost-effective in reducing cardiovascular mor-
bidity and mortality in patients further along the disease
trajectory with microalbuminuria [8,9]. It is also clear that
intensive treatment of individual cardiovascular risk fac-
tors (blood pressure and cholesterol) is beneficial [10-14].
However, it is unclear to what extent intensive multifacto-
rial treatment among screen-detected patients would be
cost-effective. Intensive treatment of hyperglycaemia
among patients with long-standing diabetes has not been
associated with cardiovascular benefits [15-17]. However,
long term follow-up of the UKPDS cohort showed that
reducing levels of blood glucose from diagnosis led to
fewer cardiovascular events [18]. It is unclear whether
intensive treatment of hyperglycaemia during the lead
time between clinical diagnosis and diagnosis by screen-
ing will be associated with similar benefits.
Ideally, there should be trial evidence of cost-effectiveness
of screening programmes before they become public pol-
icy [6], as was the case for ultrasonographic screening for
abdominal aortic aneurysm in men [19]. This is not yet
the case for type 2 diabetes. TheAnglo-Danish-Dutch
Study of Intensive Treatment In People with Screen
Detected Diabetes in Primary Care(ADDITION) trial was
set up in three countries: England (Cambridge and Leices-
ter), Denmark and The Netherlands to provide evidence
on screening for type 2 diabetes and the effects of early
intensive multifactorial treatment [20]. We present the
protocol of the Cambridge component of this trial.
Target population
If population-based screening for type 2 diabetes were to
be undertaken, current evidence supports a targeted
approach [6]. The ADDITION-Cambridge  study targets
people without known diabetes but at high risk of having
prevalent undiagnosed type 2 diabetes, identified using a
previously validated risk score [21]. This risk tool com-
bines information routinely collected in primary care,
including age, sex, body mass index and prescribed medi-
cation (steroids and antihypertensive drugs), to predict
the presence of undiagnosed diabetes. This simple practi-
cal tool has previously been shown to perform reasonably
well in different settings[22,23].
Limited evidence from previous studies
(i) The potential benefits and harms of screening
Earlier detection of diabetes and treatment of hyperglycae-
mia and related metabolic abnormalities may be benefi-
cial. Screening for hyperglycaemia can identify patients at
an early stage of the disease [24,25] who are likely to ben-
efit from intensive treatment of cardiovascular risk factors.
Patients who are given the label of diabetes may also ben-
efit from becoming involved in a more organised and
effective system of risk factor management [26]. However,
it is uncertain whether an intervention to promote inten-
sive multifactorial management for patients with screen-
detected diabetes in primary care will be cost-effective. It
is also unclear whether such an intervention might impact
on the care of other patients with established diabetes and
those at risk of diabetes in the primary care practices
undertaking intensive treatment.
Concerns have been expressed about the psychological
harms of screening programmes [27]. With the exception
of one small randomised trial undertaken in the pilot
phase of ADDITION-Cambridge [28], published data sug-
gest no or limited psychological impact of screening for
diabetes in newly detected individuals [29]. These data,
which were mainly derived from cross-sectional or cohort
studies (susceptible to selection and ascertainment bias)
were recently confirmed by the results of a controlled trial
embedded in ADDITION-Cambridge [30]. However, none
of the published studies have examined the wider impact
of screening on health related quality of life among high-BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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risk groups, the potential for a worsening of risk due to
false reassurance, or the subsequent effects of intensive
treatment on the quality of life of screen-detected individ-
uals.
Despite screening negative for diabetes, some of the high-
risk people targeted in a screening programme will exhibit
a high cardiovascular risk profile and/or develop diabetes
within a relatively short period of time given their high
lifetime risk compared to the general population [31].
Screening and promotion of early multifactorial intensive
treatment could therefore have a wider impact among
high-risk individuals as well as those diagnosed with dia-
betes as a result of screening.
Little is known about the impact at the population level
on mortality of a screening programme for diabetes. Mod-
elling studies have suggested that 4–5 yearly screening
programmes might be associated with a significant reduc-
tion in diabetes-related mortality in the order of 26–40%
[32,33]. However, this needs to be confirmed in formal
prospective studies.
(ii) The lack of trial evidence
Evaluations of screening that do not incorporate random
allocation of representative population samples are par-
ticularly susceptible to misinterpretation and overestima-
tion of benefits due to lead time, length time, spectrum,
ascertainment and selection bias [34]. Evidence from ran-
domised trials of the impact of screening is important for
public health policy decisions in view of the extensive
organisational, technical and financial inputs such a
screening programme would demand. There is no trial
evidence to suggest that early detection of type 2 diabetes
improves outcomes, or that treatment effective for clini-
cally diagnosed patients produces greater benefit when
commenced in the lead time between detection by screen-
ing and clinical diagnosis.
ADDITION-Cambridge Objectives
The primary objective of the ADDITION-Cambridge study
is to evaluate the effectiveness and cost-effectiveness of a
stepwise screening programme for type 2 diabetes and
intensive multifactorial treatment in people with screen-
detected diabetes in English general practice.
The following research questions are posed:
￿ Feasibility of screening: What uptake and yield are
achievable in a primary care-based stepwise screening
programme for type 2 diabetes?
￿ Costs of screening: What are the health service and
patient costs of screening for type 2 diabetes?
￿ Early treatment of type 2 diabetes: Can an optimised
intensive intervention targeting blood glucose and
associated cardiovascular risk factors reduce cardiovas-
cular risk and mortality in people with screen-detected
diabetes? Is this intervention cost-effective?
￿ Population level impact: Is a targeted screening pro-
gramme for type 2 diabetes associated with reductions
in population mortality and morbidity?
Methods and design
Design
ADDITION-Cambridge consists of two phases: a screening
study and a subsequent treatment study. The screening
phase examines the feasibility of a stepwise procedure to
identify people with undetected diabetes and the effects of
screening on health outcomes at the population level. The
treatment study is a pragmatic single blind, cluster-ran-
domised, parallel group trial comparing the effects of
intensive multifactorial therapy with routine care (accord-
ing to national guidelines) in individuals with screen-
detected type 2 diabetes. The evaluation of the impact of
the screening programme at the population level through
the inclusion of random allocation of practices to a no
screening (control) group is a feature specific to ADDI-
TION-Cambridge. The study design, practice and patient
flows are shown in Figures 1 and 2.
Ethical approval was obtained from the Cambridge
(ref:01/063), Huntingdonshire (ref:00/609), Peterbor-
ough and Fenland (ref:P01/95), West Essex (ref:1511-
0103), North and Mid Essex (ref:MH395 MREC02/5/54),
West Suffolk (ref:03/002), and Hertfordshire and Bed-
fordshire (ref:EC03623) Local Research Ethics Commit-
tees, and the Eastern Multi-Centre Research Ethics
Committee (ref:02/5/54). Written informed consent was
obtained for all participants involved in both phases of
the ADDITION-Cambridge study at the time of the diabe-
tes screening appointment and subsequent diagnostic
test.
ADDITION-Cambridge is registered as ISRCTN86769081.
The ClinicalTrials.gov Identifier of the whole ADDITION
Study that includes England (Cambridge and Leicester),
Denmark and the Netherlands is NCT00237549.
Setting
Patients were recruited from general practices in urban,
suburban and rural Cambridgeshire, East Hertfordshire,
West Suffolk and North Essex areas of England.
Practice recruitment
Figure 1 shows the flow of practice recruitment. 138 prac-
tices were invited to take part in the study between Sep-BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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Practice recruitment and randomisation in the ADDITION-Cambridge study Figure 1
Practice recruitment and randomisation in the ADDITION-Cambridge study.
63 practices agreed and assessed for eligibility 
60 practices randomised in two stages   
Screening plus intensive 
treatment (IT):  
15 practices
Control (no screening): 
5 practices 
Screening plus IT:  
13 practices
Screening plus routine 
care (RC): 
13 practices 
Screening plus IT arm: 
28 practices 
Screening plus RC:  
14 practices  
3 practices participated 
in pilot study
2 practices 
withdrew   
75 declined invitation 
to take part
Screening plus RC arm: 
27 practices 
4 practices 
withdrew 
First stage of randomisation:  First 33 practices allocated to three groups
Second stage of randomisation: 27 practices allocated to two groups (IT and RC)  
Control (no screening) arm: 
5 practices
Control (no screening) arm: 
5 practices
Screening plus RC arm: 
23 practices 
Screening plus IT arm: 
26 practices 
Final group allocation 
138 practices contacted to join the study BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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Participant recruitment in the ADDITION-Cambridge study Figure 2
Participant recruitment in the ADDITION-Cambridge study.
18922 participants eligible for 
screening in the 26 screening plus 
intensive treatment (IT) practices 
4137 participants eligible for
screening in the 5 control 
(no screening) practices 
452 patients diagnosed with 
diabetes and assessed at baseline
16375 participants eligible for 
screening in the 23 screening plus 
routine care (RC) practices  
Measures at one year after diagnosis of diabetes 
801 not meeting criteria 
for invitation to screen  
Personal letter of invitation and appointment sent to the participants in the screening practices 
(IT and RC arms)
957 not meeting 
criteria for
invitation to screen  
Screening plus IT group: 
17965 participants invited
Screening plus RC group:  
15574 participants invited  
415 patients diagnosed with diabetes 
and assessed at baseline 
4180 did not 
attend screening
4705 did not 
attend screening 
Identification of individuals at high-risk of undiagnosed diabetes and eligible for screening in all 
participating practices in the three arms:  39,434 individuals    
Measures at 5 years after diagnosis of diabetes BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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tember 2001 and August 2003. Personalised letters were
sent to the practice manager, partners and nursing staff in
each surgery highlighting the importance of the study to
primary care, the involvement of practice staff and the
reimbursement of all costs involved. We enclosed a brief
summary of the study and a Research Information Sheet
for Practices [35]. A principal investigator and member of
the trial team visited interested practice teams to discuss
the study in further detail. All relevant practice staff were
encouraged to attend, particularly those that would be
involved in the administration of the screening pro-
gramme. Practices were eligible if they were able to pro-
vide data for the calculation of the diabetes risk score for
at least 70% of their patients, a criterion satisfied by all 63
practices that agreed to take part.
Three practices undertook pilot testing of the screening
strategy, the baseline measures and the intensive treat-
ment materials and training. The remainder (60 practices)
were allocated to the three study arms. In the participating
practices, a "set-up" visit was undertaken to deliver prac-
tice study manuals, to provide the software developed to
assist with monitoring the progress of the screening pro-
gramme and recording of blood glucose test results, and
to train the staff in logistical and technical aspects of
screening. Further visits were arranged for practices allo-
cated to screening followed by intensive treatment to pro-
vide the materials and training to enable them to deliver
the intervention.
Practice randomisation
Randomisation of practices was completed centrally and
independently of the trial co-ordination team immedi-
ately following recruitment. The project statistician used a
partial minimisation procedure that dynamically adjusted
the randomisation probabilities to balance important
baseline practice variables: the number of patients with
known diabetes (<160 and ≥ 160 patients) and the local
district hospital (Addenbrooke's, Hinchingbrooke, Peter-
borough, Kings Lynn, Broomfield, Stevenage and Bury St
Edmunds hospitals). The first 33 practices recruited were
allocated in a ratio of 1:3:3 to the following arms: control
(no screening), screening followed by intensive multi-fac-
torial treatment of diabetes (IT), and screening plus rou-
tine care of diabetes according to national guidelines
(RC). Allocation of practices to the control (no screening)
group was stopped at N = 5. The need to increase the yield
of individuals with diabetes for the treatment trial war-
ranted the uneven randomisation ratio with a dispropor-
tionate number of screening practices and a second stage
of randomisation. 27 practices were subsequently ran-
domised in a ratio of 1:1 to IT (n = 13) and RC (n = 14).
The final group allocation after the two stages of randomi-
sation included 28 practices to IT, 27 practices to RC and
5 practices to control (no screening). Six of the 60 ran-
domised practices (2 IT and 4 RC) dropped out following
recruitment, but before screening commenced due to
other commitments or unforeseen difficulties in setting
up the practice-based screening programme.
Phase one: step-wise screening programme
(i) Eligibility for screening
Individuals eligible for an invitation for screening were
people registered with one of the participating general
practices, aged 40 to 69 years, not known to have diabetes
and with a diabetes risk score of >0.17 (corresponding to
the top 25% of the population distribution). In screening
practices, eligible participants deemed unfit for screening
by their general practitioner were not invited for biochem-
ical testing. Exclusion criteria, also assessed initially by the
participating general practitioners, included pregnancy,
lactation, an illness with a likely prognosis of less than
one year or a psychiatric illness likely to limit study
involvement or invalidate informed consent.
(ii) Participant recruitment
Figure 2 outlines the recruitment procedure. Participants
were recruited through their local general practice. An
electronic search of medical records was undertaken for
routinely collected information that would allow the cal-
culation of a diabetes risk score for each patient [21].
Information about the diabetes risk score was withheld
from practitioners in the control practices.
Figure 3 outlines the screening and diagnostic tests used to
identify people with undiagnosed diabetes. In practices in
the RC and IT groups, general practitioners wrote to all
high-risk patients, enclosing a study information sheet,
and inviting them to attend the practice for random capil-
lary blood glucose (RBG) and capillary glycosylated hae-
moglobin (HbA1c) tests, after initial consent had been
obtained. The letter was sent at least two weeks in advance
of the scheduled appointment. Patients were advised to
telephone the surgery and arrange an alternative appoint-
ment if the original was inconvenient. One reminder let-
ter was sent to non-attendees. Participants with an RBG of
≥ 11.1 mmol/l were invited for a standard 75 g oral glu-
cose tolerance test (OGTT) at one of four outpatient facil-
ities. Those with an RBG of 5.5–11.0 mmol/l were invited
to return to the practice for a fasting capillary blood glu-
cose (FBG) test. Those with an FBG of ≥ 6.1 mmol/l, or an
FBG of 5.5–6.0 mmol/l together with an HbA1c of ≥ 6.1%,
were invited for an OGTT. The RBG, FBG and OGTT were
conducted on different days. Participants with an FBG of
5.5–6.0 mmol/l and an HbA1c of ≥ 6.1% who had a posi-
tive OGTT underwent a second confirmatory OGTT on a
different day. World Health Organisation criteria were
used to diagnose diabetes [36]. Practitioners were
informed by fax about the result of clinical and biochem-
ical measures with a clear statement of whether or not theBMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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individual met diagnostic criteria for type 2 diabetes. The
general practitioner or a practice nurse then informed the
patient of the test results.
In the 54 participating practices (including the five con-
trol practices), 39,434 people aged 40–69 years were at
high risk of prevalent undiagnosed diabetes. In the 49
screening practices, 35,297 individuals aged 40–69 years
were at high-risk. 33,539 patients were invited for the first
stage of screening (RBG and HbA1c) and 24,654 (73.5%)
attended this appointment.
(iii) Outcomes
These include the number of high-risk individuals pre-
senting for screening, the number of people with newly
diagnosed type 2 diabetes, the psychological status of peo-
ple invited for screening, metabolic status, cardiovascular
risk and self-perceived health in people with newly-diag-
nosed type 2 diabetes, and health service and patient
costs. In addition we will assess the population effects of
the screening programme by comparing high-risk individ-
uals in the three study groups (IT, RC and control) using
the following measures: mortality, self-reported cardio-
vascular morbidity, health status, health utility and life-
style changes (self-reported diet, physical activity and
smoking status). Mortality will be assessed on all high-risk
individuals, while other measures will be collected in a
random sample of the high-risk population (in each of
the three groups: IT, RC and control) using a postal ques-
tionnaire. All the high-risk participants in the three study
arms are tagged at the Office of National Statistics (ONS)
for mortality, following approval under section 60 of the
UK Health and Social Care Act 2001 (Reference MR798).
Phase two: trial of intensive multifactorial treatment in 
people with screen-detected diabetes
(i) Intervention
Participants are treated routinely or intensively depending
on the study arm to which their practice was randomised
(RC or IT). The intensification of diabetes management is
achieved through the addition of the following features to
the existing diabetes care within IT practices:
￿ Funding of practices to facilitate more frequent con-
tact between patients and practitioners. The recom-
mended frequency of consultation was one 30-minute
annual review for each patient, three additional 10-
minute consultations with a GP and three with a
nurse, per year for the first three years after diagnosis,
over and above the usual consultation frequency for a
patient aged 40–69 years.
Screening algorithm used in the ADDITION-Cambridge study Figure 3
Screening algorithm used in the ADDITION-Cambridge study.
Random 
capillary blood 
glucose  
Fasting 
capillary blood 
glucose  
Standard 75g 
oral glucose 
tolerance test  
 
Stepwise screening tests in the general practice  
> 11.1 
mmol.l 
5.5 -11.0 
mmol/l  
< 5.5 
mmol/l  
5.5 - 6.0 mmol/l 
and capillary 
HbA1c 6.1 % 
 6.1 mmol/l 
< 5.5 mmol/l 
Diagnostic test in outpatient clinical research facility 
Capillary  
HbA1c also 
measured at 
this stage  
No Diabetes  BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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￿ Recommendation to the GPs to refer all newly diag-
nosed patients to a dietitian
￿ A practice-based academic detailing session for prac-
titioners conducted by a local consultant diabetologist
and a general practice opinion leader to describe the
treatment algorithms and targets, patient materials,
and present the evidence underpinning intensive treat-
ment. The treatment algorithms (Table 1) were based
on trial data demonstrating the benefits of intensive
treatment of several cardiovascular risk factors in peo-
ple with diabetes [8,13]. All treatment recommenda-
tions were for medications within their existing
licensed indications. GPs were advised to consider pre-
scribing an angiotensin converting enzyme (ACE)
inhibitor to patients with a blood pressure ≥ 120/80
mmHg and a previous cardiovascular event or at least
one cardiovascular risk factor other than diabetes [13].
The rest of the intervention is based on the stepwise
regimen from the Steno-2 study [8] aimed at optimis-
ing hyperglycaemia, hypertension, dyslipidaemia and
microalbuminuria. As per the Steno-2 regime, GPs
were advised to consider prescribing 75 mg of aspirin
daily to all patients without specific contraindications.
Although targets for treatment are specified and
classes of drugs recommended, where there is a choice
of individual agents the decision is made by the GPs
and patients. The intensive treatment protocol was
reviewed after the publication of the Heart Protection
Study [12] to include the prescription of statins to all
screen-detected patients with a cholesterol level of ≥
3.5 mmol/l.
￿ Two interactive practice-based audit and feedback
sessions were undertaken, including feedback of the
overall performance of the practice against the treat-
Table 1: Treatment recommendations in the intensive treatment arm
Target Baseline 2 months
If above
target
4 months
If above 
target
6 months
If above 
target
9 months
If above
Target
12 months
If above 
target
HbA1c <7.0% Diet HbA1c >6.5%
Metformin
(avoid using 
metformin  
if creatinine level
>130 μmol/L)
HbA1c >6.5% 
add a second 
medication
Metformin 
or PGR or 
SU or TZD
HbA1c >6.5% 
add a third 
medication
Metformin 
or  PGR or
SU or TZD
Continue oral    
hypoglycaemic
medication and
consider adding
insulin
As for 9 
months
Blood
Pressure
≤ 135/
85mmHg
>120/80 mmHg 
or CVD+
ACE Inhibitor 
titrated to
maximum dose
If bp >135/85 
mmHg 
Add a Thiazide 
diuretic or Ca
 Antagonist 
(Change
ACE to ACE2 
if creatinine
>130 μmol/L
or K+ >5.0 
mmol/L
or intolerable 
side 
effects)
As for 2 months If bp >135/85 
mmHg
Add β blocker 
orα Blocker
As for 6 months As for 6 
months
Cholesterol
†IHD-
<5.0mmol/l Chol ≥ 3.5 mmol/l, 
diet & statin
Chol >5.0 mmol/l
Increase statin
 dose up to 
maximum (If  
CK> 1800 U/L,
stop statin)
As for 2 months Consider adding a 
fibrate if
Chol >5.0 mmol/l
As for 6 months As for 6 
months
Cholesterol
IHD+
<4.5mmol/l chol ≥ 3.5 mmol/,
diet & statin
Chol >4.5 mmol/l
Increase statin 
dose up to
  maximum (If 
CK> 1800 U/L, 
stop statin)
As for 2 months Consider adding a
fibrate if 
Chol >5.0 mmol/l
As for 6 months As for 6 
months
Acetylsalycilic 
acid
75 mg of aspirin daily to all patients without specific contraindications
SU = Sulphonylurea, PGR = Prandial glucose regulator, ACE = angiotensin converting enzyme, TZD = thiazolinedione, ACE2: Angiotensin- II 
receptor Antagonist, K+: potassium, Ca: Calcium, IHD- = no history of ischaemic heart disease, IHD+ = history of ischaemic heart disease, CVD+ 
= Previous cardiovascular event or presence of cardiovascular risk factor other than diabetes, bp = blood pressure, Chol = cholesterolBMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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ment targets, the optimisation of the management of
individual patients and the reiteration of the treat-
ment targets. These were organised by the same opin-
ion leaders at six and 14 months after the initial
education session.
￿ Provision of glucometers for patients and any neces-
sary training in their use for practitioners. The decision
to offer a glucometer or not to a patient was left to the
practitioner.
￿ Practice teams were provided with a pack of theory-
based educational materials (Getting Started with Dia-
betes) to give to patients at diagnosis. The materials
provide a shared framework on the causes, conse-
quences and treatment of diabetes. The materials were
developed by a multidisciplinary team and drew on
Leventhal's self regulation model, a social cognition
model from psychology [37]. They cross-referred to
'Diabetes for Beginners-Type 2' a Diabetes UK publica-
tion [38] that was included in the patient's pack. Spe-
cifically, participants were encouraged (i) to try to lose
5–10% of their body weight (relevant if BMI>28 kg/
m2 with a target of 0.45 kg/week) through a combina-
tion of diet and physical activity; (ii) to increase their
physical activity gradually (the goal was to reach the
equivalent of 35 minutes of brisk walking per day for
7 days per week); (iii) to avoid excessive alcohol
intake; (iv) to take their medication regularly; (v) to
self-monitor their blood glucose level if given a gluco-
meter by their practice (the targets for self-monitored
blood glucose are < 9 mmol/l 90 minutes after meals,
and < 6 mmol/l before meals), and: (vi) to attend
annual checks. Participants who smoked were encour-
aged to stop.
In the RC arm, participants with screen-detected diabetes
receive the normal pattern of diabetes care as delivered
through the UK National Health Service (NHS) according
to current recommendations.
(ii) Endpoints
Primary endpoints: At one year follow-up the principle out-
come is modelled 10-year risk of cardiovascular events
derived using the UKPDS risk engine [39]. The UKPDS
model uses information on sex, ethnicity, smoking status,
presence or absence of atrial fibrillation, systolic blood
pressure, HbA1c, total cholesterol, and HDL-cholesterol to
predict the 10-year risk of primary CVD. Predicted events
are myocardial infarction, sudden cardiac death, other
incident ischaemic heart disease, stroke, and peripheral
vascular disease death. At five-year follow-up, the primary
endpoint is a composite of cardiovascular mortality and
morbidity (non-fatal myocardial infarction, non-fatal
stroke, non-traumatic amputations and revascularisa-
tions). Secondary endpoints are all-cause mortality, devel-
opment or progression of renal impairment, peripheral
neuropathy, blindness, reduced visual acuity, macular
oedema, retinopathy; health status, health utility, quality
of life, anxiety, well-being, treatment satisfaction, health
service costs (number of visits to general practitioners and
hospital doctors for outpatient clinics, hospital admis-
sions and prescribed medications). Intermediate endpoints
are self-reported smoking status, diet, physical activity
behaviour and medication adherence, HbA1c, total cho-
lesterol, LDL-cholesterol, HDL-cholesterol, triglycerides,
blood pressure, modelled 10-year cardiovascular risk (at
five-year follow-up), self reported hypoglycaemic epi-
sodes, microalbuminuria, body mass index and plasma
vitamin C.
Measurement
Table 2 shows the distribution across time of measures
relating to the screening procedure and the treatment
phase of the study. Baseline measurements were carried
out on all patients eligible for an OGTT following the
screening phase of the study. These included the comple-
tion of questionnaires, physiological and anthropometric
measures and venesection. Similar measurements are con-
ducted at one year and five years after diagnosis, without
repetition of the OGTT. The measurements at baseline,
one-year and five-year follow-up are undertaken at outpa-
tient clinical research facilities by trained staff following
standard operational procedures and unaware of partici-
pants' study group allocation. Questionnaires are used to
collect information on basic demographics, health behav-
iours, health utility, functional status and costs.
Health behaviours
Smoking status, alcohol consumption, and medication
adherence are assessed by questionnaire. Medication
adherence is assessed by the Medication Adherence
Report Schedule (MARS) questionnaire [40]. Physical
activity is assessed using the EPAQ2 [41] and IPAQ [42]
questionnaires. Dietary intake is evaluated using a vali-
dated food frequency questionnaire [43].
Health utility, functional status, quality of life, well-being, treatment 
satisfaction and anxiety
The generic and disease-specific instruments used are dia-
betes well-being questionnaire (W-BQ12) [44], SF-36
[45], SF-8 [46], Audit of Diabetes-Dependent Quality of
Life (ADDQoL) [44], diabetes treatment satisfaction
(DTS) [44], and EuroQol (EQ-5D) [47], consultation and
relational empathy (CARE) measure [48] and the Spiegel-
berger Short form State Anxiety Inventory [49].
Costs
Personal patient costs to attend initial screening tests and
health service use in the three months prior to follow-upBMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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are quantified using an adapted version of the Health
Services Research Unit Aberdeen questionnaire that
inquires about the use of services (consultations with
healthcare professionals and hospitalisations) and medi-
cations [50].
Angina is assessed using the Rose angina questionnaire
[51]. Neuropathy is evaluated using an adapted version of
the Michigan Neuropathy Screening Instrument [52].
Physiological measures
Random and fasting capillary blood glucose concentra-
tions were assessed by Hemocue (β-HemoCue AB, Angel-
holm, Sweden). The venous plasma blood glucose level is
assessed by the glucose dehydrogenase method and read
photochromatically. The stability of the analyser was
checked daily and external calibration with the Hemocue
quality assurance scheme was undertaken monthly.
HbA1c was analysed in capillary blood samples from gen-
eral practices using the Bio-Rad® system and in venous
samples at the time of diagnostic testing by ion-exchange
high-performance liquid chromatography on a Tosoh
machines (Tosoh Bioscience, Redditch, UK). Serum total
cholesterol, HDL-cholesterol and triglycerides are meas-
ured by means of enzymatic techniques (Dade Behring
Dimension analyser, Newark, USA). Plasma creatinine is
analysed with kinetic colorimetric methods, urine albu-
min by rate nephelemetry (Dade Behring Nephelometer
II, Newark, USA). Plasma levels of urea and electrolytes,
bilirubin, alanine aminotansferase (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase, and thyroid
stimulating hormone (TSH) and urine levels of creatinine
are assayed by means of the Dade Behring Dimension
analyser. Plasma vitamin C level was measured with a
Fluoroskan Ascent FL fluorometer. The albumin-to-creati-
nine ratio (ACR) is measured on a random spot urine
specimen. For assays requiring fasting, participants attend
after a 10-hour fast.
Table 2: Measures used at baseline, one-and five-years in the ADDITION-Cambridge
Measures Baseline 1-year 5-year
CR CI TCR CI TCR CI T
Diabetes risk score calculation X X X
Questionnaires measures
1. Ethnic group, occupation, educational level and social class XX
2 Smoking status, alcohol consumption XX XX XXX
3. Rose angina questionnaire [51] XX X
4. Self-reported history of angina, heart attack and stroke XX XX XXX
5. Medication adherence:
All drugs during the last month [40] XX XX XX
Hypoglycaemic drugs during the last month [40] XX XX
6. EuroQoL EQ-5D [47] & SF-36 [45]/SF-8 [46] XX XX XXX
7. Diabetes related quality of life: ADDQoL [44], Diabetes well-being: W-BQ 28 [44], Diabetes 
treatment satisfaction: DTSQ[44]
XX XX
8. Spiegelberger Short form State Anxiety inventory [49] XX XX
9. Consultation and relational empathy measure: CARE [48] XX XX
10. Diabetes knowledge † XX
11. EPAQ-2 [41] XX XX XX
12. IPAQ [42] XX XX XXX
13. EPIC food frequency questionnaire [43] XX XX XX
14. Brief dietary questionnaire (adapted from the EPIC food frequency questionnaire) † XXX
15. Costs comprising:
Personal patient costs † XX
Health Service and medication use previous 3 months (adapted from the Aberdeen Health Service 
Research Unit questionnaire) †
XX XXX
16. Neuropathy questionnaire (adapted from the Michigan Screening Instrument) † XX XX XX
Biological measures
17. Waist circumference, height, weight, blood pressure, body fat impedance and ECG XX XX XX
18. Fasting capillary blood glucose XX
19. Fasting, 30 and 120 min: venous whole blood glucose (OGTT), plasma glucose, plasma insulin. XX
20. HbA1c, total cholesterol, HDL and LDL cholesterol, triglyceride, Vitamin C, Urinalysis, Urine 
albumin/creatinine ratio, Urea and Electrolytes, Creatinine, Albumin, Biliribin, Alanine Amino 
Transferanse (ALT), Alkaline Phosphatase, Aspartate Amino Transferase (AST), Thyroid Stimulating 
Hormone (TSH)
XX XX XX
21. Modelled CVD risk calculated with the UKPDS risk engine [39] XX XX XX
22. Stereoscopic fundal photography XX
23. Mortality XXX
†: Questionnaire developed for the studyBMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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Anthropometry
Blood pressure is calculated as the mean of three measure-
ments performed after at least 10 minutes rest, while par-
ticipants are seated with the cuff on the predominant arm
at the level of the heart, using an automatic sphygmoma-
nometer (Omron M4, UK). ECG is recorded by a 12 lead
machine. Body height and weight are measured in light
indoor clothing and without shoes using a fixed rigid sta-
diometer and a scale (SECA, UK) respectively. Waist cir-
cumference is estimated as the average of two
measurements taken with a tape measure halfway
between the lowest point of the rib cage and the anterior
superior iliac crests when standing. Body fat percentage is
measured by bio-electrical impedance (TANITA, Tokyo,
Japan).
Ascertainment of mortality and cardiovascular morbidity
Macrovascular and microvascular events in patients with
screen-detected diabetes will be ascertained by a combina-
tion of strategies including electronic READ code searches
of medical records for events, and notes extraction on
potential cases of events. Anonymous case reports packs
will be prepared by a member of the research team una-
ware of participants study group allocation for independ-
ent review of each potential event by an endpoint
committee also unaware of study group allocation. All
patients will also have an ophthalmologic evaluation
including stereoscopic fundal photography at the five-
year assessment. Fundal photography will be assessed by
a separate endpoint committee blind to study groups.
ICD-10 coded mortality data is reported periodically by
the ONS for all high-risk participants in the three arms.
Assessment of the effect of screening in a random sample
of people at high risk of prevalent undiagnosed diabetes
in each of the three study groups (IT, RC and control) will
be undertaken by postal questionnaire in 2009, six years
on average post randomisation. This questionnaire
includes demographic characteristics, self-reported his-
tory of angina, heart attack and stroke, self-reported smok-
ing status, IPAQ, simple dietary behaviour questions,
EuroQoL (EQ-5D), Short Form-8 (SF-8), and the adapted
version of the Health Services Research Unit Aberdeen
questionnaire for the use of medication and services.
Costs of the intervention
The economic analysis will establish the NHS costs of the
initial screening programme for type 2 diabetes from a
patient and health service perspective. We will examine
the cost-effectiveness of the multifactorial intensive treat-
ment of patients with screen-detected type 2 diabetes from
a health service perspective.
Participant retention
The retention rate at one year follow-up was 85%. In order
to maximise retention, we are reimbursing patients' travel
at follow-up assessment. We have also been sending
annual Christmas cards to all participants. A few months
before the start of the five-year assessment, we will send a
newsletter to all participants outlining the one-year results
and plans for inviting them back for re-measurement.
Participant safety
Screening equipment was enrolled in the HemoCue qual-
ity assurance programme. The glucose tolerance test was
undertaken by trained staff in dedicated testing centres.
Treatment algorithms have been developed with advice
from local diabetes specialists who also contributed to the
initial and follow-up practice-based training sessions for
primary care staff involved in diabetes care. The responsi-
bility for prescribing and management decisions remains
with the general practitioners. Classes of medication are
only recommended within licensed indications.
In Cambridge, an independent Trial Steering Committee
meets regularly and makes recommendations on ethical
or safety aspects. At the European level, a Data Monitoring
and Ethics Committee receives periodic reports on deaths
and hypoglycaemic episodes. Termination of the study
would be determined on the basis of mortality. Based on
general trials stopping rules, it was suggested that the first
interim analysis blind to study group (using data from the
three countries) be undertaken when the total number of
deaths reaches 200. The rule for termination is a signifi-
cant difference in mortality between the IT and RC groups
at a level of significance of 0.001.
Statistical procedures
Analysis
(i) Effect of intensive multi-factorial treatment
Analysis will be by intention-to-treat allowing for cluster-
ing of patients by practice. This will be supported by sen-
sitivity analyses, assuming a range of outcomes for non-
completers informed by baseline data. The main analyses
will compare outcomes between patients with screen-
detected diabetes receiving routine care (RC) and those
receiving intensive treatment (IT), adjusting for differ-
ences in baseline variables. The primary perspective for
cost analysis will be the health service.
At one year comparisons will be made on modelled 10-
year cardiovascular disease (CVD) risk [39] and on sec-
ondary outcomes including individual cardiovascular risk
factors, health utility, functional health status, and costs.
The costs of the intensive intervention will then be com-
pared with unit change in health utility. At five-years,
analyses will include comparisons of main outcomes
(fatal and non-fatal macrovascular events) and secondary
outcomes (microvascular events, individual cardiovascu-
lar risk factors, all-cause mortality, health utility, func-
tional health status, and costs).BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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(ii) Population effects of screening
People at high risk of having undiagnosed diabetes in the
screening practices (IT and RC) will be compared to those
in the no screening (control) practices to assess the impact
of screening on mortality, cardiovascular morbidity,
health status, self-reported diet, physical activity and
health service costs using ONS and questionnaire data.
This will be done using an intention to screen analysis. For
the mortality analysis the primary outcome will be all-
cause mortality and the secondary outcomes cardiovascu-
lar, cancer and other causes of mortality. Mortality, cardi-
ovascular morbidity, health status, diet, and physical
activity among people at high risk of having undiagnosed
diabetes will also be compared between IT and RC groups
in an intention to treat analysis to quantify the potential
wider benefits of the practice-based intensive treatment
intervention package.
Sample size
The sample size calculation was based on estimates of
uptake and prevalence of undiagnosed diabetes from the
Ely study between 1990 and 1992 [53]. IT vs. RC compar-
ison of individual risk factors was originally based on
1000 screen-detected patients (500 in the IT and RC
groups). Assuming 95% confidence and 80% power and
an average practice list of 7,500 people, about 2,500 will
be aged 40–69 years. Of these around 30% (750) will be
at high risk of prevalent undiagnosed diabetes. Given a
70% uptake of screening [53] 525 would be tested and 60
would have prevalent undiagnosed diabetes per practice,
of these 42 should complete one year follow-up [54]. The
study design exhibits clustering of patients within prac-
tices. Typical values of intra-class correlations range from
0.01 to 0.1; we have previously reported correlations of
0.047 for HbA1c and 0.045 for BMI in people with diabe-
tes one year after diagnosis [54]. For clusters of 42 patients
the design effect is therefore 3 (range 1.4 to 5.0). Therefore
using our previous diabetes cohort data [53,54], (1000
screen-detected cases would allow detection of the follow-
ing clinically important differences between IT and RC
groups: 0.5% in mean HbA1c, (difference between groups
at one year in the UKPDS was 0.7% [55]), 11.5 mmHg
systolic blood pressure, 1.5 kg/m2 in body mass index,
10% in the proportion smoking, a 5 point difference in
mean EuroQol health utility index [47] and 1.3 in mean
anxiety level [49]. These estimations were initially com-
pleted for a total of 28 practices in the IT and RC arms.
Given the lower than expected prevalence of diabetes
within practices (<42 diabetic patients per practice), we
recruited more practices, hence reducing the impact of
clustering and improving the power of the study. 867
patients diagnosed with diabetes were finally enrolled.
Prior to the development and validation of a CVD risk
score incorporating glycaemic control, the original sample
size calculation was based on differences in individuals
risk factors such as HbA1c and BMI. With the increased
number of practices and smaller patients per practice,
power was re-assessed using one-year follow-up data
using risk factors making up the UKPDS ten-year mod-
elled CVD risk (excluding the unavailable but rare compo-
nent of atrial fibrillation). This was based on the initial
293 diabetic patients recruited to the RC arm of the study
and accounted for clustering (intracluster correlation of
0.0185). It was estimated that there was 90% power at the
5% level of significance to detect a relative effect of 20%
in the mean ten-year modelled CVD risk assuming one-
year retention of 70% (600 patients in 48 practices).
Discussion
ADDITION-Cambridge is designed to assess the feasibility
and cost-effectiveness of a stepwise screening and inten-
sive multi-factorial treatment programme for type 2 dia-
betes in a defined high-risk group accessible through
primary care.
A targeted stepwise approach to screening is supported by
the high proportion of undiagnosed diabetes in the UK
[53], and the low performance of screening tests as stand
alone assessments [56]. ADDITION-Cambridge  assesses
the feasibility of a combination of a diabetes risk score
with various biochemical tests as a screening strategy in
primary care. Although developed and tested in datasets
from population-based surveys [21-23], the performance
and yield of this risk score when used as part of a pro-
gramme in an existing healthcare setting remain uncer-
tain.
The treatment phase of this study has been designed to
assess the costs and benefits of early multifactorial therapy
in individuals with screen-detected diabetes with the ulti-
mate aim of reducing the risk of cardiovascular events. Tri-
als suggest that intensive treatment of people with type 2
diabetes is beneficial [8,57]. Much of the benefit of early
intervention in screen-detected diabetes would depend
upon the associated reduction of cardiovascular risk [6].
The treatment algorithm used in ADDITION-Cambridge is
based on the Steno-2 regimen [8] which was tested in clin-
ically diagnosed patients with diabetes at an advanced
stage of the disease. The effectiveness of this regimen in
people at an early stage of the disease has yet to be dem-
onstrated. The patient education aspects of the early treat-
ment programme have been informed by reviews on
interventions to prevent weight gain [58], educational and
psychosocial interventions for adults with diabetes [59],
and trials of physical activity promotion [60]. These sup-
port the view that an education programme, especially
one based on social, behavioural and psychological the-
ory and evidence, can increase the effectiveness of behav-
ioural change strategies [61,62].BMC Public Health 2009, 9:136 http://www.biomedcentral.com/1471-2458/9/136
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ADDITION-Cambridge  will provide evidence about the
benefits, harms and costs of implementing a screening
and early treatment programme for type 2 diabetes. The
results will be of relevance to policy decisions about
screening for diabetes, and subsequent management of
people early in the course of the disease. Results will also
inform approaches to health promotion, the management
of chronic disease and risk, and will have implications for
the training of practitioners in diabetes care.
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